An alternative signaling pathway, controlled by FGFR1 (fibroblast growth factor receptor 1), steps in and ensures growth and survival. "With the help of such 'bypasses,' tumors react to external ...

Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...

circulating tumor DNA (ctDNA), which is released into ... with the most frequently altered genes being TP53 (29%), PIK3CA (24%), FGFR1 (20%), and ATM (16%). Mutations in BRCA1 and BRCA2 were ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) representing the most prevalent subtypes of non-small ...

Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC ...

circulating tumor DNA (ctDNA), which is released into ... with the most frequently altered genes being TP53 (29%), PIK3CA (24%), FGFR1 (20%), and ATM (16%). Mutations in BRCA1 and BRCA2 were ...

FGFR1-targeting Pemazyre was approved by the ... At the moment, FGFR2 and FGFR3 inhibitor Balversa is only FDA-approved for bladder cancer. Around 25,000 people in Japan are diagnosed with biliary ...

The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.